Article - 13 May 2011
This article examines the features and applications of Trioctylphosphine Oxide, 99% TOPO including the physical and chemical properties supplied by Strem Chemicals
Article - 20 Jan 2005
This case study compares dynamic light scattering to other methods such as transmission electron microscopy and x-ray diffraction for the determination of particle size for Cadmium Selenide...
Article - 13 Mar 2012
Atomic force microscopes (AFMs) use a piezoelectric crystal to actuate the positioning scanner. Creep and hysteresis errors however limit the capability of measuring the sample topography. This...
News - 30 Apr 2009
FRT presents a new profilometer at this year's CONTROL 2009 in Stuttgart. The optical profiler has been optimized for the non-destructive measurement of surfaces. The MicroSpy Profile measures...
News - 15 Jan 2014
Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved its primary efficacy endpoint in an ongoing single-arm Phase 2 monotherapy...
News - 11 Sep 2013
Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced the publication of translational data on the company's lead candidate, CRLX101, currently in Phase...
Article - 26 Feb 2013
Crystalline nanoparticle arrays and superlattices can be synthesized with perfectly defined geometries using appropriate electrostatic, hydrogen bonding or biological recognition interactions.
News - 16 Apr 2015
Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that Christopher D. T. Guiffre, President and Chief Executive Officer, will present at the 14th Annual Needham...
News - 20 Oct 2015
Cerulean Pharma Inc., a clinical stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in a trial exploring a dose-intensive schedule for...
News - 16 Oct 2015
Cerulean Pharma Inc., a clinical stage company developing nanoparticle-drug conjugates (NDCs), today announced completion of enrollment of a randomized Phase 2 trial of its lead NDC, CRLX101, in...